| abstract |
The present disclosure relates to methods of treating type 1 diabetes (T1D) using glucagon receptor blockers. More specifically, the present disclosure relates to methods of treating T1D using significantly lower doses of insulin supplementation, or even without insulin supplementation, using antigen-binding and antagonistic proteins, such as those that specifically bind to human glucagon A fully human antibody that antagonizes the function of the human glucagon receptor. |